FDA inspection
PAREXEL Early Phase Clinical Unit: FDA inspection ending Oct 17, 2018
FDA inspection 1069420 · No Action Indicated (NAI) · Baltimore, MD
Key facts
| Inspection ID | 1069420 |
|---|---|
| Firm | PAREXEL Early Phase Clinical Unit |
| FEI number | 3005445577 |
| Address | Harbor Hospital, Gruehn Bldg, 3001 S Hanover St Fl 4 |
| City | Baltimore |
| State | MD |
| ZIP | 21225 |
| Country | United States |
| Fiscal year | 2019 |
| Inspection end date | Oct 17, 2018 |
| Classification | No Action Indicated (NAI) |
| Project area | Bioresearch Monitoring |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data